The Australian market has shown resilience despite global uncertainties, with investors cautiously optimistic following recent geopolitical developments and trade discussions. In such a climate, penny stocks—though an outdated term—remain relevant as they highlight smaller or less-established companies that can offer significant value. By focusing on those with strong financials and clear growth potential, investors may uncover promising opportunities among these under-the-radar stocks. Top 10 Penny Stocks In Australia Name Share Price Market Cap Financial Health Rating Alfabs Australia (ASX:AAL) A$0.48 A$137.56M ★★★★★☆ Dusk Group (ASX:DSK) A$0.945 A$58.84M ★★★★★★ IVE Group (ASX:IGL) A$2.67 A$410.95M ★★★★★☆ MotorCycle Holdings (ASX:MTO) A$3.10 A$228.8M ★★★★★★ Pureprofile (ASX:PPL) A$0.043 A$50.3M ★★★★★★ Veris (ASX:VRS) A$0.069 A$36.34M ★★★★★★ West African Resources (ASX:WAF) A$3.04 A$3.47B ★★★★★★ Praemium (ASX:PPS) A$0.82 A$391.73M ★★★★★★ Service Stream (ASX:SSM) A$2.23 A$1.37B ★★★★★★ CTI Logistics (ASX:CLX) A$1.855 A$149.41M ★★★★☆☆ Click here to see the full list of 425 stocks from our ASX Penny Stocks screener. We'll examine a selection from our screener results. Aroa Biosurgery Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix technology in the United States and internationally, with a market cap of A$244.97 million. Operations: The company's revenue is primarily generated from its operations in developing, manufacturing, and selling soft tissue repair products, amounting to NZ$84.70 million. Market Cap: A$244.97M Aroa Biosurgery, with a market cap of A$244.97 million, is gaining attention due to its innovative ENIVO platform for surgical applications, which shows promise in addressing complications like seromas post-mastectomy. Despite being unprofitable and having a negative return on equity of -4.1%, the company has no debt and strong short-term asset coverage over liabilities. Its earnings have grown by 21.2% annually over five years, reducing losses significantly. Trading well below estimated fair value and with an experienced management team, Aroa presents an intriguing opportunity in the penny stock segment as it pursues commercialization efforts for ENIVO technology. Unlock comprehensive insights into our analysis of Aroa Biosurgery stock in this financial health report. Learn about Aroa Biosurgery's future growth trajectory here.ASX:ARX Debt to Equity History and Analysis as at Oct 2025 LGI Simply Wall St Financial Health Rating: ★★★★★☆ Overview: LGI Limited operates in Australia, offering carbon abatement and renewable energy solutions through the utilization of biogas from landfills, with a market cap of A$362.38 million. Story Continues Operations: The company's revenue is derived from Carbon Abatement (A$17.29 million), Renewable Energy (A$17.08 million), and Infrastructure Construction and Management (A$2.37 million). Market Cap: A$362.38M LGI Limited, with a market cap of A$362.38 million, has recently been added to the S&P/ASX Emerging Companies Index. The company reported A$36.78 million in sales for the year ending June 2025, driven by its carbon abatement and renewable energy segments. Despite a decline in net profit margins from 20.1% to 17.6%, LGI's debt management is robust, with a net debt to equity ratio of 20.2% and operating cash flow covering debt well at 43.2%. Although earnings growth was negative over the past year, forecasts suggest potential annual growth of around 25%. Navigate through the intricacies of LGI with our comprehensive balance sheet health report here. Gain insights into LGI's future direction by reviewing our growth report.ASX:LGI Financial Position Analysis as at Oct 2025 Tyro Payments Simply Wall St Financial Health Rating: ★★★★★★ Overview: Tyro Payments Limited offers integrated payment solutions and value-added services in Australia, with a market cap of A$602.76 million. Operations: The company generates revenue from its Payments segment, which accounts for A$460.86 million, and its Banking segment, contributing A$14.78 million. Market Cap: A$602.76M Tyro Payments Limited, with a market cap of A$602.76 million, has demonstrated resilience in the penny stock segment despite challenges. The company's revenue from its Payments and Banking segments totaled A$475.64 million for the year ending June 2025, though net income declined to A$17.82 million from A$25.71 million previously. Tyro's short-term assets exceed both its short-term and long-term liabilities, indicating solid financial footing without debt concerns. However, recent earnings growth has been negative at -30.7%, contrasting with a forecasted annual growth rate of 7.96%. Experienced management and board teams bolster operational stability amidst fluctuating profit margins. Click here to discover the nuances of Tyro Payments with our detailed analytical financial health report. Gain insights into Tyro Payments' outlook and expected performance with our report on the company's earnings estimates.ASX:TYR Debt to Equity History and Analysis as at Oct 2025 Taking Advantage Get an in-depth perspective on all 425 ASX Penny Stocks by using our screener here. Searching for a Fresh Perspective? We've found 19 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:ARX ASX:LGI and ASX:TYR. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected] View Comments
3 Promising ASX Penny Stocks With Market Caps Under A$700M
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...